Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.38 |
| ▸ | RET | P07949 | 6/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29782960 | 0.87 | ACACB (0.40) | ACACBHCRTR2HCRTR1RET | |
| SCHEMBL29749185 | 0.81 | PDE10A (0.41) | ACACBRET | |
| SCHEMBL26918920 | 0.79 | ACACB (0.43) | ACACBRETGRIN2DGRIN3BGRIN1 | |
| SCHEMBL26918962 | 0.79 | ACACB (0.43) | ACACBRETGRIN2DGRIN3BGRIN1 | |
| SCHEMBL31144052 | 0.76 | HCRTR2 (0.38) | ACACBHCRTR2HCRTR1RETGRIN2D | |
| SCHEMBL28701004 | 0.76 | HCRTR2 (0.38) | ACACBHCRTR2HCRTR1RETGRIN2D | |
| SCHEMBL28840055 | 0.71 | GRIN2D (0.41) | ACACBHCRTR2HCRTR1RETGRIN2D | |
| SCHEMBL29782901 | 0.70 | PDE10A (0.48) | RETGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20474698 | 0.65 | AKR1C3 (0.49) | ACACBRETKDM4EGRIN2DGRIN3B | |
| SCHEMBL29782973 | 0.65 | ACACB (0.44) | ACACBRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | ACACB 4590/4885HCRTR2 2750/4885HCRTR1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.